Abstract:Purpose: Recent studies indicated that RUNX3 exhibits potent antitumor activity. However, theunderlyingmolecularmechanisms of this activity remainunclear. In the present study, weused a gastric cancer model to determine the effect of RUNX3 expression on tumor angiogenesis. Experimental Design: The effects of increased RUNX3 expression on vascular endothelial growth factor (VEGF) expression in and angiogenic potential of human gastric cancer cells were determined in vitro and in animal models. RUNX3 and VEGF expression was determined in 120 human gastric cancer specimens and their relationship was analyzed. Results: RUNX3 gene transfer suppressed VEGF expression in human gastric cancer cells. Down-regulationofVEGF expression correlatedwith a significantly impaired angiogenicpotential of human gastric cancer cells. Furthermore, RUNX3 restoration inhibited tumor growth and metastasis in animalmodels, whichwas consistent with inhibition of angiogenesis as determined by evaluating VEGF expression and tumor microvessel formation. In gastric cancer specimens, loss or decrease in RUNX3 expression inversely associated with increasedVEGF expression and elevated microvessel formation. Conclusions: Our clinical and experimental data provide a novel molecular mechanism for the antitumor activity of RUNX3 and may help design effective therapy targeting RUNX3 pathway to control gastric cancer growth and metastasis. Although the incidence of gastric cancer declined in the West from the 1940s to the 1980s, it remains a major public health problem throughout the world (1). In Asia and parts of South America in particular, gastric cancer is the most common epithelial malignancy and leading cause of cancer-related death. Moreover, gastric cancer remains the second most frequently diagnosed malignancy worldwide and cause of 12% of all cancer-related deaths each year (1, 2). Advances in the treatment of this disease are likely to come from a fuller understanding of its biology and behavior. The aggressive nature of human metastatic gastric carcinoma is related to mutations of various oncogenes and tumor suppressor genes (3–7) and abnormalities in several growth factors and their receptors (5). These abnormalities affect the downstream signal transduction pathways involved in the control of cell growth and differentiation. Specifically, they confer a tremendous survival and growth advantage to gastric cancer cells. Previous studies indicated the role of several tumor suppressor genes in gastric cancer development and progression, including the E-cadherin/CDH1 gene, TP53, and p16 (3, 6, 8–11) and, most recently, runt-related (RUNX) genes (12). The human RUNX genes encode the a-subunit of the runt domain transcription factor PEBP2/CBF (13) and are homologues to the Drosphila genes runt (14) and lozenge (15). The mammalian and Drosphila RUNX genes share an evolutionarily conserved region of 128 amino acids, termed the runt domain, required for DNA binding and heterodimerization with the h-subunit PEBP2/CBF (13). All three runt domain family members, RUNX1, RUNX2 , and RUNX3 , are master regulators of gene expression in major developmental pathways and play pivotal roles in cell proliferation and differentiation in humans (16–18). Recent studies have also linked alterations of RUNX genes with carcinogenesis (12, 19–24). A drastic loss of RUNX3 expression correlates with poor prognosis of gastric cancer patients (25). Inactivation of RUNX3 seems to be caused by several mechanisms, including promoter hypermethylation (silencing) and protein mislocalization in cancer cells (25, 26). However, the molecular basis for the alteration of this novel putative tumor suppressor and its effect on cancer biology is largely unclear. Moreover, it is completely unknown Human Cancer Biology Authors’Affiliations:Departments of General Surgery and Pathology, Shanghai Jiaotong University Affiliated First People’s Hospital; Cancer Center, Tongji University Affiliated East Hospital, Shanghai, China; and Departments of Gastrointestinal Medical Oncology and Cancer Biology,The University of Texas M.D. Anderson Cancer Center, Houston,Texas Received10/28/05; revised 4/24/06; accepted 6/28/06. Grant support: Natural Science Foundation of The People’s Republic of China (Z. Peng), American Cancer Society Research Scholar grant CSM-106640, and National Cancer Institute, NIH grant1R01-CA093829 (K. Xie). The costs of publication of this article were defrayed in part by the payment of page charges.This article must therefore be hereby marked advertisement in accordance with18 U.S.C. Section1734 solely to indicate this fact. Note: Z. Peng, D.Wei, and L.Wang contributed equally to this work. Requests for reprints: Keping Xie, Department of Gastrointestinal Medical Oncology, Unit 426,The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston,TX 77030. Phone: 713-792-2828; Fax: 713-7451163; E-mail: kepxie@mail.mdanderson.org. F2006 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-05-2359 www.aacrjournals.org Clin Cancer Res 2006;12(21) November1, 2006 6386 Research. on May 26, 2017. © 2006 American Association for Cancer clincancerres.aacrjournals.org Downloaded from whether and, if so, how RUNX3 regulates angiogenesis and growth and metastasis of gastric cancer. Like with other solid tumors, the growth and metastasis of gastric cancer depend on angiogenesis, which is the formation of new blood vessels from a pre-existing network of capillaries (27). Of the numerous angiogenic factors discovered thus far, vascular endothelial growth factor (VEGF; ref. 28) has been identified as a key mediator of tumor angiogenesis. Elevated expression of VEGF in human tumor biopsy specimens has been reported in cases of various cancers, including gastric cancer (2, 29, 30). In addition, increasing evidence suggests that VEGF expression is regulated by a plethora of external factors (28, 31). Moreover, loss or inactivation of tumor suppressor genes and activation of oncogenes are associated with VEGF overexpression (29–31). Thus, both genetic and epigenetic alterations involve in VEGF expression and regulation (31). It is important to determine whether RUNX3 directly regulates VEGF expression. In the present study, we examined the relationship between the expression of RUNX3 and VEGF expression and microvessel density (MVD) status in tumor tissue specimens obtained from patients with resected gastric cancer. We found that lost RUNX3 expression directly correlated with increased VEGF expression and tumor angiogenesis. We also found for the first time that restoration of RUNX3 expression dramatically suppressed the angiogenic potential of human gastric cancer cells, which correlated with down-regulation of VEGF expression via promoter repression in vitro, and attenuation of tumorigenecity and abrogation of metastasis in animal models. Our clinical and mechanistic data provide a novel molecular basis for the antitumor activity of RUNX3 and for targeting RUNX3 pathway to control human gastric cancer. Materials andMethods Human tissue specimens and patient information. We used human gastric cancer tissue specimens preserved in the Gastric Cancer Tissue Bank at Shanghai Jiaotong University Affiliated First People’s Hospital (Shanghai, China). Primary gastric cancer in these patients was diagnosed and treated at the hospital from 2000 to 2002. None of them underwent preoperative chemotherapy and/or radiation therapy. We selected 120 cases to represent all of the stages and histologic types of malignant gastric cancer. Specifically, the patients consisted of 75 (62.5%) men and 45 (37.5%) women; 64 (53.3%) ages V60 years and 56 (46.7%) ages >60 years with mean age of 60.5 years; 67 (55.8%) intestinal type, 39 (32.5%) diffuse type, and 14 (11.7%) mixed type; 17 (14.2%) tumor-node-metastasis stage (TNM) I, 26 (21.7%) TNM stage II, 64 (53.3%) TNM stage III, and 13 (10.8%) TNM stage IV (Table 1). All tissues were obtained with patient consent for the present study and all laboratory work involving in human specimens was approved by the Institutional Review Board of and done at Shanghai First People’s

Abstract:Purpose:We determined the expression of mammalian target of rapamycin (mTOR) and its activated form, p-mTOR, in Chinese patients with gastric cancer and its clinical effects and underlying mechanisms. Experimental Design:Tissue microarray blocks containing gastric cancer tissue and matched noncancer gastric tissue specimens obtained from1,072 patientswere constructed. Expressionof total mTOR and p-mTOR in these specimens was analyzed using immunohistochemical studies and confirmed byWestern blotting. Results: The overall rates of total mTOR and p-mTOR overexpression were 50.8% (545 of 1,072) and 46.5% (499 of 1,072), respectively. The p-mTOR overexpression was significantly correlated with total mTOR overexpression. Overexpression of total mTOR protein was significantly correlated with tumor differentiation, T1/T2 tumors, and stage I/II/III disease, whereas p-mTOR overexpression was significantly correlated with lymph node metastasis and all stage disease. The Cox proportional hazards model revealed that the overexpression of p-mTOR, but not total mTOR, was an independent prognostic factor for gastric cancer. The overexpression of p-mTOR also predicted the angiogenic phenotype of human gastric cancer and regulated angiogenesis of gastric cancer cells. Conclusions: Increased activation of mTOR is frequent in human gastric cancer and overexpression of p-mTOR is an independent prognostic factor, suggesting that mTOR pathway could be a potential target for therapy of this malignancy. Gastric cancer is the second leading cause of cancer-related deaths worldwide. More than one-third of all gastric cancer cases occur in China (1, 2). Researchers have described many biological markers associated with gastric cancer progression and outcome and observed differences in survival and clinicopathologic prognostic factors in patients with this disease in different countries and racial and ethnic groups within given populations and areas (3–8). Molecules involved in several signaling pathways were potential prognostic and therapeutic markers (9, 10). Determining the expression profiles of key molecules in the survival pathways in gastric cancer progression may aid in diagnosing and predicting disease progression. Because of their potential roles in gastric cancer progression, the phosphatidylinositol 3-kinase-dependent pathway and angiogenesis pathway have become the foci for development of novel anticancer drugs (9), including mammalian target of rapamycin (mTOR). The mTOR is a serine/threonine downstream mediator in phosphatidylinositol 3-kinase signaling pathway. Physiologically, mTOR is a central controller of eukaryotic cell growth and proliferation and plays a critical role in regulating important cellular functions, including proliferation, growth, survival, mobility, and angiogenesis (10, 11). Authors have reported activation of the mTOR pathway and overexpression of mTOR in several types of tumors, including hepatocellular (12), renal cell (13), prostate (14), and breast (15) cancers. Moreover, patients with breast cancer who had mTOR overexpression had a risk of recurrence three times greater than that in patients without mTOR overexpression (15). Lang et al. (16) recently reported overexpression of p-mTOR in 60% of intestinal-type and 64% of diffuse-type human gastric cancer cases and that Imaging, Diagnosis, Prognosis Authors’Affiliations: Department of Medical Oncology, Changzheng Hospital; Department of Pathology, Changhai Hospital, Shanghai, People’s Republic of China; Department of Dermatology and Skin Science, Jack Bell Research Centre, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, British Columbia, Canada; and Departments of Gastrointestinal Medical Oncology and Cancer Biology,The University of Texas M. D. Anderson Cancer Center, Houston,Texas Received 8/18/08; revised 10/20/08; accepted 11/3/08; published OnlineFirst 02/17/2009. Grant support: Ministry of Science and Technology of the People’s Republic of China, National KeyTechnology R&DProgram grant 2006BAI02A05 (J.Wang and G.Yu) and America Cancer Society research scholar grant CSM-106640 (K. Xie). The costs of publication of this article were defrayed in part by the payment of page charges.This article must therefore be hereby marked advertisement in accordance with18 U.S.C. Section1734 solely to indicate this fact. Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/). Requests for reprints: Jiejun Wang, Department of Medical Oncology, Changzheng Hospital, Hetian Road 64, Shanghai 200070, People’s Republic of China; Shanghai. Phone: 86-21-66540109-7045; Fax: 86-21-56327477; E-mail: jiejunw@csco.org.cn; or Keping Xie, Department of Gastrointestinal Medical Oncology,The University of Texas M. D. Anderson Cancer Center, Unit 426, 1515 Holcombe Boulevard, Houston,TX 77030. Phone: 713-792-2828; Fax: 713-7451163; E-mail: kepxie@mail.mdanderson.org. F2009 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-08-2138 www.aacrjournals.org Clin Cancer Res 2009;15(5) March1, 2009 1821 Research. on April 11, 2017. © 2009 American Association for Cancer clincancerres.aacrjournals.org Downloaded from inhibition of expression of mTOR significantly impaired gastric cancer cell migration and proliferation. However, the role of mTOR activation in gastric cancer carcinogenesis and progression is poorly understood. The clinical significance of the expression mTOR protein and particularly the activated form of p-mTOR in patients with gastric cancer also remains unclear. Angiogenesis is a complex process and a crucial step in tumor formation and progression. This process is regulated by a balance between proangiogenic and antiangiogenic molecules. Among numerous proangiogenic factor, vascular endothelial growth factor (VEGF) has been established as the major angiogenic factor (17). Frequently observed in gastric cancer (18–20), overexpression of VEGF closely correlates with lymph node metastasis (21), liver metastasis (22), age (23), and tumor size (24) and often indicates a poor prognosis (25, 26) and therapy resistance (27). Although VEGF is constitutively expressed in many tumor cells, its expression is subject to several regulatory mechanisms (17). The potential role of mTOR pathway in VEGF regulation is supported by several recent studies, showing that inhibition of mTOR associated with a decreased VEGF expression (28–30). Given the critical role of VEGF in cancer angiogenesis in general, those recent findings suggest a critical link between mTOR activation and VEGF-mediated angiogenesis in gastric cancer. The present study sought to provide both clinical and experimental evidence for the significance of mTOR activation in gastric cancer and the potential underlying mechanisms of its effect on gastric cancer pathogenesis, particularly angiogenesis. Materials andMethods Patient specimens and tissue microarray construction. A total of 1,072 patients with gastric adenocarcinoma who underwent curative surgery without prior treatments at Changhai Hospital from 2001 to 2005 were enrolled in this study. Patients with other gastric tumors, such as neuroendocrine tumors, lymphoma, and sarcoma, were excluded from this study. The patients’ medical records were reviewed to obtain data including age at diagnosis, sex, tumor location, tumor size (diameter), nerve invasion, and American Joint Committee on Cancer stage. The mean age of patients at tumor resection was 59 years; 757 (71%) were male and 315 (29%) were female. Clinical follow-up results were available only for 669 patients from the Shanghai area (mean follow-up duration, 37 months; range, 21-73 months). Twentyone paraffin-embedded tissue microarray blocks of gastric tumor, matched normal gastric, and lymph node metastasis tissue specimens obtained from those patients were created using a manual arrayer (Beecher Instruments). Each block had two 1.5 mm cores of primary tumor tissue and at least one 1.5 mm core of matched nonneoplastic mucosal tissue. For patients with lymph node and/or liver metastasis, one or two 1.5 mm cores of metastatic tissue were included. Of the primary gastric cancer specimens, 57.6% (618 of 1,072 cases) were intestinal-type and 42.4% (454 of 1,072 cases) were diffuse-type according to the Lauren classification. Other patient characteristics are listed in Table 1. All of the tissue specimens were obtained for the present study with patient informed consent, and the use of the human specimens was approved by the Changhai Hospital Institutional Review Board. Immunostaining and evaluation. Consecutive sections (4 Am) of paraffin-embedded tissue microarrays blocks were prepared and processed for immunohistochemical analysis as described previously (7). Total mTOR, p-mTOR, and VEGF protein expression in the sections was detected with appropriate antibodies against total mTOR (dilution, 1:50; clone Y391; Abcam), p-mTOR (Ser; dilution, 1:100; clone 49F9; CST), and VEGF (dilution, 1:200; clone SP28; Lab Vision). Total mTOR, p-mTOR, and VEGF protein expression in those 1,072 cases was evaluated by two individuals using an Olympus CX31 microscope (Olympus Optical). A semiquantitative scoring system was used as described previously (7). Specifically, a underexpression was defined as no staining or staining positivity in tumor tissue being less than matched normal tissue, a normal expression as staining positivity being similar to matched normal tissue, and an overexpression as staining positivity being higher than normal tissue. Staining was scored independently by two individuals who were blinded to each other’s findings. All conflicting calls on scoring were adjudicated by a third individual. Quantification of tumor microvessel density. For CD34 staining, formalin-fixed, paraffin-embedded tumor tissue sections were processed and stained with a monoclonal goat anti-CD34 (PECAM

RUNX 3 Inhibits the Expression ofVascular Endothelial Growth Factor and Reduces theAngiogenesis , Growth , and Metastasis of Human Gastric Cancer

Runx3 Inhibits The Expression Of Vascular Endothelial Growth Factor And Reduces The Angiogenesis, Growth, And Metastasis Of Human Gastric Cancer

Prognostic significance of RUNX3 expression in human melanoma.

Reappraisal of the impacts of human Runt-related transcription factor gene 3 expression on differentiation and prognosis of gastric cancer

Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis

Tumor Suppressor Gene Runx3 Sensitizes Gastric Cancer Cells to Chemotherapeutic Drugs by Downregulating Bcl‐2, MDR‐1 and MRP‐1

Overexpression of PhosphorylatedMammalianTarget of Rapamycin Predicts Lymph NodeMetastasis and Prognosis of Chinese Patients with Gastric Cancer

Runx3 Suppresses Gastric Cancer Metastasis Through Inactivation Of Mmp9 By Upregulation Of Timp-1

EFFECTS OF RUNX3 ON CELL TURNOVER IN GASTRIC CANCER AND ITS PROGNOSTIC VALUE

RUNX3, a Novel Tumor Suppressor, is Frequently Inactivated in Gastric Cancer by Protein Mislocalization.

RUNX2 promotes gastric cancer progression through the transcriptional activation of MGAT5 and MMP13

Activation of STAT3 in Human Gastric Cancer Cells Via Interleukin (Il)-6-type Cytokine Signaling Correlates with Clinical Implications

Hypermethylation Downregulates Runx3 Gene Expression and Its Restoration Suppresses Gastric Epithelial Cell Growth by Inducing P27 and Caspase3 in Human Gastric Cancer

RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells.

Expression and significance of Runt-related transcription factor 3 gene and DNA methyltransferase 1 in gastric cancer

RUNX3 inhibits survivin expression and induces cell apoptosis in gastric cancer.

RUNX3 Promotes the Tumorigenic Phenotype in KGN, a Human Granulosa Cell Tumor-Derived Cell Line.

Preliminary study of expression and modulating factors of runt-related transcription factor 3 and their methylation in human gastric cancer cell lines

Inhibition of the Growth and Metastasis of Human Colon Cancer by Restoration of RUNX3 Expression in Cancer Cells.

VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer

Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.